Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Roth, Christian

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Cohen, Pinhas / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Toppari, Jorma

Editorial Board Member: Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / Hiort, Olaf / LaFranchi, Stephen H. / Lanes M. D., Roberto / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Zadik, Zvi

12 Issues per year

IMPACT FACTOR 2016: 1.233

CiteScore 2016: 1.09

SCImago Journal Rank (SJR) 2015: 0.493
Source Normalized Impact per Paper (SNIP) 2015: 0.600

See all formats and pricing
In This Section
Volume 24, Issue 11-12 (Dec 2011)


Effect of GnRH analogue on height potential in patients with severe growth hormone insensitivity syndrome treated with IGF-I

Mohamed El Kholy
  • Department of Paediatrics, Ain Shams University, Cairo, Egypt
/ Heba H. Elsedfy
  • Department of Paediatrics, Ain Shams University, Cairo, Egypt
  • Email:
Published Online: 2011-11-01 | DOI: https://doi.org/10.1515/JPEM.2011.348


Children with growth hormone insensitivity syndrome (GHIS) who receive insulin-like growth factor 1 (IGF-1) treatment and enter puberty with inadequate height gain are unlikely to reach adult height within the normal range. Final height standard deviation score (SDS) in most treated children is ≤-5. Combining IGF-1 with gonadotrophin-releasing hormone analogue (GnRHa) therapy may help to improve their final height. Three patients on IGF-1 treatment, two with primary GHI and one with secondary GHI, were started on GnRHa therapy at the onset of puberty. Their ages ranged from 6.4 years to 12.9 years at the start of IGF-1 therapy (120 μg/kg twice daily by subcutaneous injection). Gains in height/bone age SDSs under GnRHa therapy ranged from 0 to 0.9. Growth velocity on GnRHa therapy ranged from 4 cm/year to 4.8 cm/year. Bone maturation (measured as change in bone age divided by change in chronological age, ΔBA/ΔCA) decreased after the start of GnRHa therapy. Predicted adult height (PAH) improved in two patients and was maintained in one. Bone mineral density showed gradual improvement from baseline. Treatment with GnRHa resulted in a gain in PAH. Final height results will provide the definite answer on the effectiveness of this combined treatment.

Keywords: GnRH analogue therapy; growth hormone insensitivity; IGF-I therapy; Laron syndrome

About the article

Corresponding author: Heba H. Elsedfy, 11 Shafik Ghorbal Street, Heliopolis, Cairo 11341, Egypt Phone: +202 2258 4743, +202 01051 89166

Received: 2011-07-11

Accepted: 2011-09-03

Published Online: 2011-11-01

Published in Print: 2011-12-01

Citation Information: Journal of Pediatric Endocrinology and Metabolism, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/JPEM.2011.348.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Yingjie Wu, Hui Sun, Jelena Basta-Pljakic, Luis Cardoso, Oran D Kennedy, Hector Jasper, Horacio Domené, Liliana Karabatas, Clara Guida, Mitchell B Schaffler, Clifford J Rosen, and Shoshana Yakar
Journal of Bone and Mineral Research, 2013, Volume 28, Number 7, Page 1575

Comments (0)

Please log in or register to comment.
Log in